Apolipoprotein B
Lipids marker
ApoB
Apolipoprotein B
Protein found on all atherogenic lipoprotein particles (LDL, VLDL, IDL, Lp(a)). Each particle carries exactly one ApoB molecule, making it a direct count of atherogenic particles. Considered a more accurate cardiovascular risk predictor than LDL alone.
PED Notes
Superior to LDL for assessing cardiovascular risk in PED users. AAS worsen ApoB levels -- oral compounds are particularly harmful. Unlike LDL (which measures cholesterol content), ApoB counts the actual number of atherogenic particles, which better predicts arterial plaque buildup. Target <0.9 g/L for primary prevention, <0.7 g/L for high-risk individuals.
When high
Supplements:
- Citrus Bergamot -- 500mg 2x/day
- Red Yeast Rice -- as directed
- Omega-3 (EPA/DHA) -- 2-3g/day
- Increase dietary fibre, reduce refined carbs
Pharmacological options (when supplements are insufficient or ApoB target <0.7 g/L is required):
- Rosuvastatin -- 5-20mg/day; first-line; preferred over atorvastatin/simvastatin in AAS users due to lower CK elevation risk; monitor CK and ALT
- Ezetimibe -- 10mg/day; cholesterol absorption inhibitor; combine with statin for additive ApoB reduction; useful as stand-alone for statin-intolerant athletes
- Bempedoic acid -- 180mg/day; ATP-citrate lyase inhibitor; statin alternative for athletes who develop CK elevation on statins (not taken up by muscle)
- PCSK9 inhibitors (alirocumab 75mg or evolocumab 140mg subQ q2 weeks) -- for resistant cases or where ApoB target <0.7 g/L is required (active PED user with multiple risk factors); ~50-60% ApoB reduction
- All require physician oversight and baseline liver/CK panel
History Chart
Reading History
Frequently Asked Questions
Reference Ranges
Standard Range
VitalMetrics Range